<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02980887</url>
  </required_header>
  <id_info>
    <org_study_id>16-860</org_study_id>
    <nct_id>NCT02980887</nct_id>
  </id_info>
  <brief_title>Pulmonary Vascular Disease Phenomics Program PVDOMICS</brief_title>
  <acronym>PVDOMICS</acronym>
  <official_title>Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics (PVDOMICS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is recognized that patients with various forms of heart and lung disease exhibit varying&#xD;
      degrees of pulmonary hypertension, pulmonary vascular remodeling, and right ventricular&#xD;
      dysfunction. The genetic, molecular, and cellular processes driving these phenomena are not&#xD;
      well understood. Rapid advances in high throughput omic methodology, combined with powerful&#xD;
      bioinformatics and network biology capability, have created the opportunity to conduct&#xD;
      studies that broadly search for homologies and differences across the spectrum of disease&#xD;
      states associated with pulmonary hypertension, and determinants of the spectrum of right&#xD;
      ventricular compensation that accompanies these conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol is designed to lead to new understanding of patients with pulmonary hypertension&#xD;
      and right heart dysfunction, based on molecular, clinical, hemodynamic and radiographic&#xD;
      characteristics. New classifications will be a product of association of these in depth&#xD;
      phenotypic descriptions with specific molecular mechanisms of pathogenesis. The protocol will&#xD;
      be implemented to lead to identification of both sub-phenotypes of lung vascular disease and&#xD;
      to biomarkers of disease that may be useful for early diagnosis or for assessment of&#xD;
      interventions to prevent or treat this condition.&#xD;
&#xD;
      A longitudinal study in a subset of the participants enrolled in the parent cross-sectional&#xD;
      study will:&#xD;
&#xD;
        1. Retest participants at a minimum 6 month interval from initial evaluation to collect a&#xD;
           core set of clinical and OMICS features. This will include survival, clinical staging,&#xD;
           clinical group assignment, 6-minute walk, echocardiography, and blood for a broad&#xD;
           collection of selected OMICS tests, to include proteomics and other variables found to&#xD;
           be informative in the initial set.&#xD;
&#xD;
        2. Associate and compare OMICS data with clinical sets and OMICS clusters between baseline&#xD;
           and follow-up interval, with attention to reproducibility, predictive capacity as&#xD;
           biomarkers for diagnosis, disease progression, phenotypic changes, functional capacity,&#xD;
           therapeutic response and survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Precision based definitions of pulmonary vascular diseases (PVD)</measure>
    <time_frame>Over 5 years</time_frame>
    <description>OMICs analyses will be used to assign new class of PVD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of biomarkers for PVD</measure>
    <time_frame>5 years</time_frame>
    <description>OMICs and other measures of disease</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy controls No intervention as this is an observational study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Vascular Disease</arm_group_label>
    <description>Pulmonary Vascular Disease at risk for pulmonary hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
    <description>Those meeting WSPH/WHO group classifications 1-5 of pulmonary hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>There is no intervention in this observational study</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
    <arm_group_label>Pulmonary Vascular Disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples for Omics analyses, including DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary hypertension, Pulmonary hypertension vascular, and healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Cross-sectional (parent) study:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Patients ages &gt;18 years of age referred for right heart catheterization for further&#xD;
        evaluation of known PVD or to be at risk for PVD due to established cardiac disease or&#xD;
        pulmonary disease&#xD;
&#xD;
          -  Able to perform complete diagnostic testing listed subsequently (cardiac&#xD;
             catheterization, echo, exercise test, PFT's, ECG, chest CT, quality of life&#xD;
             questionnaires, ventilation/perfusion scan, cardiac MRI, body composition&#xD;
             bioimpedance, and sleep study)&#xD;
&#xD;
          -  Subject signs informed consent to perform required testing for the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Dialysis dependent renal function; In the clinician's opinion, too ill to perform the&#xD;
        protocol testing; Pregnant or nursing&#xD;
&#xD;
        Longitudinal study:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Any PH, comparators or control participant previously enrolled in the parent PVDOMICS&#xD;
             protocol with a minimum of six months post-enrollment&#xD;
&#xD;
          -  Dialysis dependent renal function since the parent study acceptable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participant Level 1 (clinic visit):&#xD;
&#xD;
          -  Transplant other than heart or lung&#xD;
&#xD;
          -  In the clinician's opinion, too ill to perform L-PVDOMICS testing even if limited&#xD;
             testing.&#xD;
&#xD;
          -  Participants who withdrew from the parent PVDOMICS study&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Concurrent participation in any investigational drug study or other clinical trial&#xD;
&#xD;
        Participant Level 2 (telephone visit):&#xD;
&#xD;
          -  Transplant other than heart or lung&#xD;
&#xD;
          -  Participants who withdrew from the parent PVDOMICS study&#xD;
&#xD;
        Participant Level 3 (medical chart review):&#xD;
&#xD;
        - Participants who withdrew from the parent PVDOMICS study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas S Hill, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tufts University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Xiao, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pvdstudy.ccf.org/pvd/</url>
    <description>PVDOMICS study protocol</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan for sharing with outside network investigators is being developed.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Being decided</ipd_time_frame>
    <ipd_access_criteria>Being decided</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

